GSK Shifts R&D Hub from Stevenage to Cambridge in £400 Million Investment
Over 1,000 scientists to staff new facility, phased move by 2029.
Carla Rooney
GSK will close its primary research and development hub in Stevenage, relocating operations to a new facility in Cambridge.
The new Cambridge R&D centre will house over 1,000 scientists; staff from Stevenage are slated for a phased transition expected to conclude by 2029.
The Stevenage R&D site currently employs approximately 1,800 staff; their future roles hinge directly on these relocation plans.
Luke Miels, GSK's Chief Commercial Officer, confirmed the investment will "accelerate our R&D and help us deliver new, competitive products."
integrates GSK further into one of the world’s leading centres of knowledge and demonstrates the attractiveness of the UK’s life sciences ecosystem.
Miels also stated the move "integrates GSK further into one of the world’s leading centres of knowledge and demonstrates the attractiveness of the UK’s life sciences ecosystem."
Tony Wood, GSK's Chief Scientific Officer, highlighted Cambridge's established reputation, noting the city "has built one of the world’s best life sciences ecosystems, with leading universities, hospitals and biotech companies."
Wood further emphasised the collaborative opportunities presented by the new campus, stating it "provides exceptional opportunities for collaboration."
He added, "With our existing connections and experience, we see this move as a catalyst for faster, bolder medicines discovery by accelerating the science that matters most for GSK’s next wave of medicines."
Historically, pharmaceutical R&D often spread across multiple, smaller sites; this new Cambridge centre exemplifies a modern trend towards integrated, large-scale scientific ecosystems.
The relocation places GSK directly within a vibrant academic and commercial nexus; Cambridge boasts a formidable concentration of scientific talent and infrastructure, including institutions like the University of Cambridge and numerous biotech start-ups.
This strategic shift forms part of a broader initiative to achieve £1.9 billion in cost savings over three years, earmarked to fund increased R&D efforts and help offset the financial impact when dolutegravir loses its patent protection.
Luke Miels confirmed, "To fund investment in the late-stage portfolio and R&D, we are starting a three-year cost savings programme to simplify the organisation and to reallocate capital and resources."
Miels also stated, "Savings will primarily be reinvested, with some used to improve margins and profitability in the dolutegravir patent expiry period."
The company plans to advance at least 20 potential medicines into late-stage trials this year, indicating a sharp focus on prioritisation.
Increased ruthlessness in prioritisation drives the company's strategic decisions; investors reportedly applaud such moves.
The share price shows increased activity; the patent cliff appears less daunting. Stakeholders across the political spectrum will scrutinize this investment, with Andy Burnham describing the move as "a vote of confidence in British business."
a vote of confidence in British business.
Public perception also plays a role; expectations for job creation and medical breakthroughs run high.
Economically, the £400 million outlay positions GSK to compete aggressively in the global pharmaceutical market, targeting enhanced efficiency and accelerated drug discovery.
GSK claims some roles will experience impact from the changes; the company did not confirm specific numbers, but some support service roles are understood to be affected.
GSK expects all Stevenage workers to relocate to either Cambridge or Ware, despite claims that the company will announce sweeping job cuts.